Maze Therapeutics has reported promising topline results from its Phase 2 HORIZON trial for MZE829, an oral small-molecule dual-mechanism APOL1 inhibitor. The study demonstrated a significant 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR) at week 12 among patients with APOL1-mediated kidney disease, with half of the participants achieving a reduction exceeding 30%. Notably, patients with focal segmental glomerulosclerosis experienced an impressive 61.8% mean reduction in uACR.

These findings are particularly relevant as they highlight MZE829’s potential therapeutic impact on a patient population often resistant to current treatments. The trial’s design, which allowed participants to maintain stable background therapies like SGLT2 inhibitors and GLP-1 receptor agonists, underscores the drug’s compatibility with existing treatment regimens.

As Maze Therapeutics prepares to advance MZE829 into a pivotal program, the results could pave the way for new therapeutic strategies in managing APOL1-mediated kidney diseases, a critical area of focus in longevity and healthspan research.

Source: longevity.technology